Dizincare Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 2 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
About Dizincare Pharmaceuticals
Dizincare Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 August 2022 (Two years and five months 22 days old ). Its registered office is in Bardhaman, West Bengal, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Subir Das, Kunal Bute, and Bipad Das serve as directors at the Company.
Company Details
-
Location
Bardhaman, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230WB2022PTC256497
-
Company No.
256497
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Aug 2022
-
Date of AGM
25 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Dizincare Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subir Das
|
Director | 20-Aug-2022 | Current |
|
Kunal Bute
|
Director | 20-Aug-2022 | Current |
|
Bipad Das
|
Director | 20-Aug-2022 | Current |
Financial Performance of Dizincare Pharmaceuticals.
Enhance accessibility to Dizincare Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dizincare Pharmaceuticals?
Unlock access to Dizincare Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Operonic LlpKunal Bute is a mutual person
-
Carezcap Healthcare Llp
Kunal Bute is a mutual person
-
Manincure India Private Limited
Kunal Bute is a mutual person
-
Krabitten (Opc) Private Limited
Kunal Bute is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dizincare Pharmaceuticals?
Dizincare Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dizincare Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dizincare Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.